Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)
Authors:
Open Access
- 25 November 2021
- Vol. 6 (6) , 100325
Abstract
No abstract availableKeywords
Funding Information
- Novartis Pharma
- Merck Sharp and Dohme United Kingdom
- Bristol-Myers Squibb
- Taiho Pharmaceutical
- Eisai
- Novartis
This publication has 30 references indexed in Scilit:
- MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 CasesClinical Cancer Research, 2017
- Characteristics of melanoma in Japan: a nationwide registry analysis 2011–2013Melanoma Research, 2017
- Whole-genome landscapes of major melanoma subtypesNature, 2017
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled AnalysisJournal of Clinical Oncology, 2017
- Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patientsJournal of Dermatological Science, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Epidemiology and survival outcomes of ocular and mucosal melanomas: A population‐based analysisInternational Journal of Cancer, 2013
- Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive casesBMC Cancer, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Somatic Activation of KIT in Distinct Subtypes of MelanomaJournal of Clinical Oncology, 2006